Gong, Jifang
Cao, Junning
Zhang, Qingyuan
Xu, Nong
Zhao, Yanqiu
Xing, Baocai
Miao, Zhanhui
Wu, Yilong
Pan, Hongming
Gao, Quanli
Li, Xingya
Liu, Baorui
Li, Wei
Pei, Zhidong
Xia, Hongqiang
Qi, Qinzhou
Dai, Hangjun
Shi, Qingmei
Yang, Jianxin
Li, Jin
Shen, Lin http://orcid.org/0000-0003-1134-2922
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
https://doi.org/10.1007/s00262-021-03102-3
Funding for this research was provided by:
CStone Pharmaceuticals
National Key Research and Development Program of China (No. 2017YFC1308900)
Article History
Received: 25 May 2021
Accepted: 27 October 2021
First Online: 5 January 2022
Declarations
:
: Dr. Y. Wu reported receiving honoraria from AstraZeneca, Eli Lilly and Company, Pfizer, Roche, and Sanofi. H. Xia, Q. Qi, H. Dai, Q. Shi, and J. Yang are paid employees of CStone Pharmaceuticals. Other authors declared no conflict of interest.
: Study procedures were approved by an independent ethics committee at each study center.
: All patients provided written informed consent.
: All authors have approved the submission and publication of the manuscript.